RNC Capital Management LLC Lowers Stock Position in Sanofi (NASDAQ:SNY)

RNC Capital Management LLC lessened its holdings in Sanofi (NASDAQ:SNY) by 13.9% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 5,352 shares of the company’s stock after selling 865 shares during the period. RNC Capital Management LLC’s holdings in Sanofi were worth $258,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of SNY. Jennison Associates LLC raised its stake in shares of Sanofi by 938.0% during the 3rd quarter. Jennison Associates LLC now owns 1,904,445 shares of the company’s stock worth $109,753,000 after acquiring an additional 1,720,972 shares in the last quarter. Thrivent Financial for Lutherans increased its stake in Sanofi by 28,890.2% during the 3rd quarter. Thrivent Financial for Lutherans now owns 1,429,219 shares of the company’s stock valued at $82,366,000 after purchasing an additional 1,424,289 shares in the last quarter. DAVENPORT & Co LLC increased its stake in Sanofi by 40.7% during the 4th quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company’s stock valued at $110,715,000 after purchasing an additional 664,455 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Sanofi by 20.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock valued at $133,172,000 after purchasing an additional 399,301 shares in the last quarter. Finally, Franklin Resources Inc. increased its stake in Sanofi by 13.1% during the 3rd quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock valued at $208,106,000 after purchasing an additional 395,744 shares in the last quarter. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on SNY. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Finally, Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Two investment analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, Sanofi presently has an average rating of “Buy” and an average target price of $60.00.

Sanofi Stock Up 0.9 %

NASDAQ:SNY opened at $53.35 on Friday. The company’s fifty day moving average price is $49.72 and its 200-day moving average price is $52.37. Sanofi has a 1-year low of $45.22 and a 1-year high of $58.97. The firm has a market capitalization of $135.39 billion, a P/E ratio of 21.43, a PEG ratio of 1.26 and a beta of 0.57. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 0.74.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, meeting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.58%. As a group, equities research analysts anticipate that Sanofi will post 4.34 EPS for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.